Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death
BMC Cancer volume 5, Article number: 161 (2005)
Neuroblastoma is a solid tumour of childhood often with an unfavourable outcome. One common genetic feature in aggressive tumours is 1p-deletion.
The α-enolase (ENO1) gene is located in chromosome region 1p36.2, within the common region of deletion in neuroblastoma. One alternative translated product of the ENO1 gene, known as MBP-1, acts as a negative regulator of the c-myc oncogene, making the ENO1 gene a candidate as a tumour suppressor gene.
Methods used in this study are transfection of cDNA-vectors and in vitro transcribed mRNA, cell growth assay, TUNEL-assay, real-time RT-PCR (TaqMan) for expression studies, genomic sequencing and DHPLC for mutation detection.
Here we demonstrate that transfection of ENO1 cDNA into 1p-deleted neuroblastoma cell lines causes' reduced number of viable cells over time compared to a negative control and that it induces apoptosis. Interestingly, a similar but much stronger dose-dependent reduction of cell growth was observed by transfection of in vitro transcribed ENO1 mRNA into neuroblastoma cells. These effects could also be shown in non-neuroblastoma cells (293-cells), indicating ENO1 to have general tumour suppressor activity.
Expression of ENO1 is detectable in primary neuroblastomas of all different stages and no difference in the level of expression can be detected between 1p-deleted and 1p-intact tumour samples. Although small numbers (11 primary neuroblastomas), there is some evidence that Stage 4 tumours has a lower level of ENO1-mRNA than Stage 2 tumours (p = 0.01). However, mutation screening of 44 primary neuroblastomas of all different stages, failed to detect any mutations.
Our studies indicate that ENO1 has tumour suppressor activity and that high level of ENO1 expression has growth inhibitory effects.
Neuroblastoma is the most common solid tumour of childhood. It is a tumour of the postganglionic sympathetic nervous system. The most common genetic features of this tumour are amplification of the oncogene MYCN, deletions of part of chromosome arm 1p, gain of parts of 17q and triploidy. MYCN amplification, 1p-loss and 17q gain are strongly associated with aggressive tumour and unfavourable outcome for the patient, whereas triploidy is associated with low stage neuroblastomas and a favourable outcome. For review see .
A smallest region of overlap of deletion has earlier been determined in primary neuroblastomas by our group to an approximately 2 Mbp region between polymorphic markers D1S214 and D1S244 [2, 3]. Although other research groups have defined regions telomeric to marker D1S214 , still the major part of all 1p-deleted neuroblastoma tumours does include this region. We hypothesise that this region harbours one or more tumour suppressor genes, which plays an important role in neuroblastoma tumourigenesis. In previous studies a number of different candidate genes from the critical region have been screened for mutations and expression differences. Some examples are TP73[5, 6], CORT , DFFA [8, 9], UBE4B , APITD1 , KIF1B-beta , KIF1B-alpha , SDHB , CDC2L1 [15, 16], HKR3 , DAN , ID3 , TNFR2 . However, there is still no conclusive evidence that anyone of these candidate genes could function as a neuroblastoma tumour suppressor gene.
Functional evidence for a neuroblastoma tumour suppressor gene on chromosome 1 was obtained in cell-hybrid studies . The addition of an entire chromosome 1 to a 1p-deleted cell line was shown to induce cell death and/or differentiation indicating that it should be possible to functionally identify the neuroblastoma tumour suppressor gene by introducing candidate genes into 1p-deleted neuroblastoma cells, and then monitoring the cells for reduced cell growth, apoptosis and differentiation.
Non-neural enolase or α-enolase (ENO1) is an enzyme in the glycolytic pathway catalysing the formation of phosphoenolpyruvate from 2-phosphoglycerate. This gene also encodes an alternatively translated product, by initiating the translation at the Met-97 residue in exon 5 . This product was earlier known as the Myc-binding protein-1 (MBP-1) . The long 48 kDa form of α-enolase has enzymatic activity and, depending on cell type, a cytoplasmic and/or nuclear localization , whereas the shorter 37 kDa form (MBP-1) is preferentially localized in the cell nuclei . MBP-1 appears to function as a negative regulator of c-myc expression . The c-myc protooncogene is a DNA-binding phosphoprotein that plays an important role in cell growth regulation and differentiation . A major genetic feature of aggressive neuroblastoma tumours is amplification of the oncogene MYCN, and this is often associated with loss of chromosome region 1p. Even though there are similarities between the c-myc and MYCN oncogenes, there is no evidence that MBP-1 is able to interact with MYCN. Still it would be of interest to investigate this further by comparing the actions of ENO1/MBP-1 in MYCN-amplified cells relative to cells with no MYCN-amplification.
Enforced overexpression of MBP-1 by transfection of MBP-1 cDNA into human breast carcinoma cells was shown to inhibit tumour formation in nude mice , and the carboxyl-terminal repressor domain of MBP-1 has been shown to regress prostate tumour growth in nude mice . Another study has shown that α-enolase is frequently down-regulated in non-small cell lung cancer and that low levels of α-enolase predicts aggressive biological behaviour . Our first hypothesis in designing this study was that the shorter form (MBP-1) would play an important role in cell growth regulation in neuroblastoma, considering its localization to the nucleus and its known function as a negative regulator of c-myc expression, and that the longer form (ENO1) would not be directly involved in altered cell growth. This hypothesis was proven to be false, since we in this study could show that the longer form (ENO1) alone has equal or stronger effect on the cell viability and apoptosis, as do MBP-1.
In this paper we have functionally screened six candidate genes from the 1p36.2 region (CORT, DFFA, ENO1, ICAT, PEX14 and PGD) in neuroblastoma cells. We have furthermore performed a more detailed study of ENO1, including its shorter translation form MBP-1, and a mutated form of ENO1 that eliminates the possibility of production of MBP-1, by using in vitro transcribed mRNA. Our studies demonstrate that ENO1 overexpression in both neuroblastoma and 293 cells significantly reduces cell growth and induces apoptosis, implicating ENO1 in tumourigenesis. Similar effects could be seen for both ENO1 and MBP-1 in both MYCN-amplified cells (IMR32) and cells with no MYCN-amplification (SK-N-AS).
Full length IMAGE cDNA clones of the genes DFFA [GenBank:BC000037], ENO1 [GenBank:BC009912], ICAT [GenBank:BC014300], PEX14 [GenBank:BC006327], PGD [GenBank:BC000368] (HGMP Resource Centre, UK) and a clone for CORT [Genbank:AF013252] (Incyte Genomics, Palo Alto, CA) were used as templates to make a full length PCR product not including the polyA signal and introducing cloning sites in the ends (primer sequences available upon request). For DFFA, ENO1, ICAT and CORT a NotI site was introduced at the 3' end and an EcoRI site at the 5' end. For clones PGD and PEX14 NotI was used at both ends. The PCR products were digested and ligated into the vector pIRES-EGFP (Clontech, Palo Alto, CA), which includes the CMV promoter for eukaryotic expression and the EGFP gene for fluorescence detection, using standard procedures. The resulting clones of DFFA, PEX14 and PGD were also confirmed by restriction digestion (data not shown). Large-scale plasmid DNA preparations were performed using the Qiagen Plasmid Maxi protocol (Qiagen, Hilden, Germany). All constructs were finally sequence confirmed by BigDyeTerminator sequencing, performed on ABI 3700 (Applied Biosystems).
A mutated variant of the ENO1 cDNA was constructed by introducing two mutations in the ENO1 sequence, eliminating the alternative translation start codons of MBP-1 (Fig. 1A). The mutations were introduced into the ENO1 sequence by PCR using the double-mutated forward primer fp1: 5'-CTGATCATCGAGATCGA TGGAAC-3', in combination with the reverse primer rp2: 5'-ACAAAGAATTCCGG GGATCTAGCCT GTGG-3' for 30 cycles, using the ENO1-pIRES-EGFP construct as a template. 0.1 μl of the PCR-product was then used as template in an additional PCR reaction using the primers fp3: 5'-CAGCAGCGGCCGCTTCCTCTC CTAGGCG-3' and rp2: 5'-ACAAAGAATTCCGGGGATCTAGCCTGTGG-3' for 30 cycles of PCR, to incorporate the mutations in the full-length gene product. The ENO1 mutant fragment was cloned into the pIRES-EGFP vector by EcoRI/NotI digestion and religation (Fig. 1B). The mutations were also confirmed by digestion of the PCR product with BclI and ClaI that only digest the mutated sequence (Fig. 1C).
Production of in vitrotranscribed mRNA
A DNA fragment containing the coding region of the ENO1 gene linked to the Sp6 promoter sequence and a polyA tail at the end of the fragment was constructed by PCR. The primers used for the ENO1 and ENO1mut mRNAs were fp: 5'-ATTTAGGTGACACTATAGAAGAGACCCAGTGGCTAGAAGTTCACCATG-3' and rp: 5'-GG(T)30CCGGGGATCTAGCCTGTGG-3'. Similarly, the primers for MBP-1 mRNA were fp: 5'-ATTTAGGTGACACTATAGAAGAGAACAAGAGAAGATTGACAAACTGATG-3' and rp: 5'-GG(T)30CCGGGGATCTAGCCTGTGG-3' using ENO1-mut-pIRES-EGFP-vector as a template. The PCR was performed using High Fidelity Taq Polymerase (Roche, Mannheim, Germany) according to supplier's protocol with an annealing temperature of 58°C and 25 cycles of PCR.
500 ng of the PCR-product (663 bp) was used as a template for in vitro mRNA using mMESSAGE mMachine (Ambion, Austin, TX). The procedure was according to supplier's protocol using 4 hours incubation at 37°C. The mRNA was DNaseI treated for 15 min at 37°C and LiCl-precipitated before size and concentration evaluation by agarose gel electrophoresis. The control EGFP mRNA was produced using an EcoRI-digested Sp6-EGFP vector as template in the in vitro mRNA reaction.
The concentrations of EGFP and ENO1 mRNA preparations were evaluated on agarose and adjusted to be equal for transfection studies.
The 1p-deleted neuroblastoma cell lines SK-N-AS and IMR32 (MYCN-amplified) (ATCC, Manassas, VA), the human kidney derived cell line 293 and the human erythroleukaemic cell line K562 were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% Fetal Calf Serum (FCS) at 37°C using standard procedures. On the day before transfection the cell lines were split into new culture flasks and their viability tested by Trypan Blue staining. Flasks with 60–80% cell confluence were used in transfection experiments. Immediately before the transfection procedure the SK-N-AS cells, the IMR32 cells and the 293 cells were trypsinized and washed twice with PBS and the cell numbers were calculated using Trypan Blue staining. The suspension cells K562 were used only if the viability was 90% or more on the day of transfection.
Transfection of cDNA vectors
Transfection of the cell lines SK-N-AS and 293 with the cDNA constructs was performed by electroporation using 10 μg of DNA in 4 × 106 cells in a 0.4 cm cuvette in 500 μl Opti-MEM I (Invitrogen, Carlsbad, CA) at 300 V, 950 μF, ∞ Ω, using a Bio-Rad Gene Pulser II (Bio-Rad, Hercules, CA). The transfection efficiency of SK-N-AS and 293 was tested by transfection of the plasmid pEGFP-N22, followed by estimation of the number of green cells detected by FACS analysis after two days of growth in DMEM 10 % FCS. The transfection efficiency for the SK-N-AS and 293 cells was approximately 90% under these conditions.
For IMR32 cells, transfections were performed using Lipofectamine™ 2000 (Invitrogen). 12 μg of DNA and 25 μl of Lipofectamine™ 2000 in 1200 μl Opti-MEM I were used for transfecting 106 cells in 5 ml of DMEM, 10% FCS. Transfection efficiency was estimated to be 60 % by fluorescence microscopy of pEGFP-N22 transfected cells, two days after transfection.
Transfection with all plasmid constructs was performed twice using SK-N-AS cells. The ENO1 construct and empty vector control were also transfected in four different experiments into SK-N-AS cells and twice into IMR32 and 293 cells.
Transfection of mRNA
The transfections were performed in a 12-well plate using 4 × 105cells/well for SK-N-AS and K562 cells and 7 × 105 cells/well for 293 cells, all in 2 ml DMEM with 10% FCS per well. For each transfection a total of 1.5 μg of mRNA (A: 1.5 μg EGFP mRNA; B: 0.3 μg ENO1 mRNA + 1.2 μg EGFP mRNA; C: 1.5 μg ENO1 mRNA) and 5 μl Lipofectamine™ 2000 were used. The mRNA and the Lipofectamine™ 2000 were incubated together for 30 min in 200 μl Opti-MEM I and then added to the cell suspensions. The cells were immediately divided into 96-well plates at 104 cells/well (SK-N-AS, K562) or 1.7 × 104 cells/well (293) (50 μl/well), and incubated at 37°C for 5 hours before an extra 50 μl DMEM with 10% FCS was added. The cells were incubated for 1–4 days in 37°C for cell growth studies.
After transfection, the cells were allowed to attach for two hours in a tissue culture plate (6 well) before the medium was replaced by fresh DMEM 10% FCS. Then the cells were grown for two days before all cells, both in medium and attached cells (trypsinized) were washed with PBS and fixed in a final concentration of 2% paraformaldehyde.
The fixed cells were TUNEL stained using the In Situ Cell Death Detection Kit TMR-red kit (Roche, Mannheim, Germany) according to supplier's protocol. This stains all apoptotic cells red. The cells were then analysed by FACS analysis.
Cell growth assay
After transfection, the cells were divided into 96-well plates. Cells with each different construct were divided into 8 wells/plate, in four different plates with 104 cells in 100 μl DMEM 10 % FCS per well. One plate was used every day for four days after transfection to monitor cell growth. 20 μl of CellTiter96 Aqueous One Solution (Cell Proliferation Assay, Promega, Madison, WI) was added to each well and incubated in a humid dark chamber at 37°C for four hours. The absorbance was detected at 490 nm by an ELISA-reader (Labsystems Multiscan RC, Helsinki, Finland). The results were compared to a standard curve to calculate the number of viable cells per well each day. The mean number of cells in the 8 wells evaluated per day per construct was used in evaluating the results.
The transfection efficiency was evaluated one day after transfection using fluorescence microscopy, by counting the number of green cells in the pEGFP-N22 or EGFP mRNA experiments.
Frozen (-70°C) tumour samples from 44 neuroblastoma patients; 4 Stage 1 (1 1p-deleted), 4 Stage 2, 14 Stage 3 (7 1p-deleted), 20 Stage 4 (14 1p-deleted), 2 Stage 4S; 2 ganglioneuromas and 2 teratomas (1 1p-deleted) were used in the study.
The tumours were staged according to the International Neuroblastoma Staging System criteria [31, 32]. The 1p-deletion status has been previously evaluated [2, 16]. DNA was extracted from patient samples using standard procedures.
Expression studies of ENO1
Total RNA was extracted from frozen neuroblastoma tumour tissue from 11 primary neuroblastomas; 4 Stage 2 tumours from patients with no evidence of disease after treatment; 7 Stage 4 tumours (4 1p-deleted), all from patients dead of disease and 7 neuroblastoma cell lines (4 1p-deleted) using RNeasy RNA extraction kit (Qiagen). 2.4 μg total-RNA of each sample was reversed transcribed to cDNA using Superscript II (Amersham, Buckinghamshire, UK) and random hexamer primers, all according to supplier's protocol.
Real time RT-PCR
TaqMan primers and probes were derived from the commercially available TaqMan® Assays-on-Demand Gene Expression Products. To select the most appropriate endogenous control for the real-time RT-PCR quantification analysis of neuroblastoma primary tumours, we used TaqMan Human Endogenous Control Plate (catalog number: 4309921, Applied Biosystems, Foster City, CA). Analysis was performed according to supplier's protocol.
To select the most appropriate endogenous control for the real-time PCR quantification analysis, we tested eight different primary NB samples of different stages for their expression levels of ten commonly used housekeeping genes. GUSB (β-glucuronidase) and B2M (β2-microglobulin) showed least variations in ΔCT levels, and were expressed at constant levels in all samples regardless of NB-stage. GUSB was selected, and further used as an internal reference for normalization in the real-time PCR quantification analysis .
Real-time RT-PCR was performed in 384-well plates using ABI PRISM® 7900HT Sequence Detection System (Applied Biosystems). Amplification reactions (10 μl) were carried out in duplicate with 1 μl of 1:10 diluted template cDNA according to manufacturer's protocol (Applied Biosystems). In each assay, a standard curve with six cDNA dilutions was recorded and two non-template controls were included.
Quantification was performed by the standard-curve method. The mean CT-value for duplicates was calculated, and the gene concentration (or gene copy number) of test samples was interpolated based on standard curves. All samples were normalized by dividing the concentration of the test gene with the concentration of the housekeeping gene β-glucuronidase (GUSB) in the same cDNA sample.
Statistical analysis was done with Student's two-sided t-test on each group of tumors; low-stage and high stage tumors; and for 1p-deleted and not 1p-deleted tumors for the expression study.
In the transfection study, Student's two-sided t-test was used to compare cell numbers in each experiment at 1, 2, 3 and 4 days after transfection.
Mutation screening of all exonic sequences, selected intronic sequences and the promoter region of ENO1 was performed on genomic DNA from 48 primary neuroblastoma tumours of all different stages. The different regions were amplified by PCR and the PCR products were screened for mutations using either BigDyeTerminator sequencing, performed on ABI 3700 (Applied Biosystems) and/or DHPLC (WAVE) (Becton, Dickinson and Company) all according to general protocols of the suppliers. PCR-primers were designed to include the entire exon plus exon-intron boundaries. PCR primers and amplification data are available on request.
TUNEL staining, followed by FACS-analysis, of ENO1-transfected SK-N-AS neuroblastoma cells two days after transfection showed a higher degree of apoptotic cells (59%) than with the empty vector control (9%) or any of the other constructs tested (8–26% apoptotic cells), (Table 1, Fig. 2).
The DNA transfection studies also showed that the ENO1 gene did have the strongest and most consistent effect (approximately 20% reduction) on the growth rate of 1p-deleted neuroblastoma cells (SK-N-AS and IMR32) compared to an empty vector control (Table 2, Fig. 3). In the same assay, DFFA, PGD and PEX14 showed an approximately 10% reduction in cell growth (SK-N-AS), ICAT did not show any reduction and CORT showed very variable effects (from -10% to 18% reduction) (Table 2, Fig. 3). Transfection experiments using the ENO1-gene compared to empty vector control were also performed in the 1p-deleted and MYCN-amplified neuroblastoma cell line IMR32 and the non-neuroblastoma cell line 293. These experiments showed that ENO1 reduced cell growth by 20–30 % in all three cell lines (Table 2).
Interpretation of cell growth studies after transfection of plasmids carrying various genes may be complicated by the fact that only a fraction of cells express the relevant gene, whereas the growth of the remaining cells may continue unaffected. In an effort to ensure that most cells express the relevant gene after transfection, we have also investigated transfection of each one of the genes as in vitro transcribed mRNA. Preliminary studies with EGFP-mRNA showed that the transfection efficiency, as determined by fluorescence microscopy 24 hours after transfection, was 90% for SK-N-AS cells, 60% for K562 cells and 90% for 293 cells.
Our mRNA-transfection experiments showed that by adding 1.5 μg of ENO1- or ENO1-mut-mRNA to the neuroblastoma cell line SK-N-AS, the cell numbers were reduced by 60% after 24 hours, and by 80% after 2–4 days of incubation, compared to EGFP-mRNA transfected cells (Table 3, Fig. 4A &4B). On the other hand, 1.5 μg MBP-1-mRNA reduced the cell growth rate by 50% after 24 hours and 70% 2–4 days after transfection (Table 3, Fig. 4B), indicating that MBP-1-mRNA is less effective than the full length transcripts.
When 0.3 μg ENO1-mRNA or ENO1-mut-mRNA mixed with 1.2 μg of EGFP-mRNA were used, the reduction in cell numbers after 24 hours was 40%, and 60% respectively after 2–4 days. As with the 1.5 μg experiment, 0.3 μg MBP-1-mRNA mixed with 1.2 μg of EGFP-mRNA gave a lower reduction of 30% after 24 hours, and 40% 2–4 days after transfection (Table 3, Fig. 4C).
In 293 cells a large reduction in cell numbers in the 1.5 μg ENO1-mRNA experiments could be seen after 24 hours (50%), and after 2–4 days (90%) compared to EGFP transfected control cells (Table 3, Fig. 4A). For 1.5 μg MBP1- or ENO1-mut-mRNA the reduction in 293 cells was 40% after 24 hours, and 70–80% 2–4 days after transfection. A parallel experiment with 0.3 μg ENO1-mRNA showed about 60% reduction 2–4 days after transfection compared to control cells, while in the same experiment ENO1-mut and MBP-1 mRNAs showed a 30% and a 50% reduction respectively (Table 3).
In K562 cells, the cell numbers 24 hours after transfection were not significantly different between experiments (Table 3).
No difference in expression levels could be detected between 1p-deleted cell lines (average relative concentration of 1.07) and 1p-intact cell lines (average relative concentration of 1.08). Also in Stage 4 neuroblastoma primary tumours, no difference in ENO1-expression could be detected between 1p-deleted (average relative concentration 0.25) and 1p-intact samples (average relative concentration of 0.19) (Fig. 5).
Real time-PCR studies of the ENO1 gene on cDNA-samples showed a 55% reduction (p = 0.01) of ENO1-mRNA levels in stage 4 neuroblastoma tumours compared to stage 2 tumour levels (average relative concentration of 0.5 in stage 2 tumours compared to 0.23 in stage 4 tumours). This reduction was independent on the 1p-deletion status of the tumour sample (Fig. 5).
The mutation screening of the promoter region and of all exonic sequences of ENO1, including exon/intron boundaries, and of introns 5–7 in 48 primary neuroblastoma samples of different stages did not reveal any mutations (data not shown).
The aim of this study was to functionally identify a tumour suppressor gene in the commonly deleted region 1p36 in advanced stage neuroblastoma tumours. We were in fact able to identify one gene, ENO1, located in the smallest region of overlap of deletion in neuroblastoma, which did seem to have tumour suppressor activity. That is, by introducing this gene as a cDNA construct into neuroblastoma cells, the number of viable cells over time was reduced, and the number of apoptotic cells was increased. These two results are probably just two ways of monitoring the same thing. A higher degree of cell death will obviously slow down number of viable cells over time. We also tested the ability of ENO1 cDNA to slow down cell growth in other cell types that did not have a deletion of 1p. Here we choose the 293 cell line (human transformed kidney cells). Other cells that could add valuable information would be a neuroblastoma cell line with intact 1p (such as SK-N-SH or SK-N-F1), we were though unable to get a satisfactory transfection efficiency in these cell lines for this study, and thus choose to use the 293 cells that worked very well, that also adds valuable information about the general effect of ENO1 on cells with intact 1p. In this study we monitor viable cells over time after transfection, thus it is crucial to have high percentage of transfected cells otherwise your experiment would easily be overgrown by the untransfected cell population. After transfection of ENO1 into the 293 cells the same results were obtained as with the neuroblastoma cell lines, that is, the number of viable cells over time was reduced by 20–40 %. These results are concordant with the results of Ray and co-workers that transfection of MBP-1 into human breast carcinoma cells showed reduction of cell growth and inhibition of tumour formation in nude mice . MBP-1 was later demonstrated to be a shorter translational variant of the ENO1 gene [22, 25]. The localization of the gene in the 1p36.2 chromosomal region makes it a very interesting gene for neuroblastoma tumourigenesis and one hypothesis is that one deleted copy of ENO1 in the neuroblastoma cells would result in lower levels of α-enolase, and thus these cells would have a stronger response when more ENO1-mRNA is added. However, in this study we did see an equally strong effect in the chromosome 1 intact cells 293. Maybe the level of ENO1 is crucial in the cells, and by adding too much of this gene product shifts the balance easily and makes the cell go into apoptosis. Also we could see in the ENO1-expession study that the 1p-deleted cell lines did not have lower levels of ENO1-mRNA compared to the 1p-intact cell lines. This adds to the hypothesis that the level of ENO1 expression might be crucial. One hypothesis was that it might be a difference in the response to added ENO1 in MYCN-amplified cells (IMR32) and cells with normal MYCN (SK-N-AS), since the shorter form of ENO1 (MBP-1) appears to function as a negative regulator of c-myc expression . No difference could however be seen in the response in these two cell lines, indicating that ENO1 has growth inhibitory properties independent of effects on MYCN regulation.
We could not detect a consistent reduction in cell growth with the other gene constructs tested. Also we could not detect any clear increase in apoptotic cell numbers (Table 1), and no obvious signs of differentiation, although our data do not fully exclude a role for one or more of these genes in the development of neuroblastoma. Noteworthy is also another gene, APITD1, recently localised to this region of interest. APITD1 could be shown to slow down cell growth and induce apoptosis in neuroblastoma cells . We can hypothesise that if a number of genes in this specific region have tumour suppressor activity, a small reduction in expression of all these genes can give a substantial effect on cell growth. A recent study has indeed shown that there are numerous genes from the 1p36-region down-regulated in aggressive neuroblastoma tumours .
In order to further investigate the ability of ENO1 to slow down cell growth, and to compare the different translation products of ENO1 in a functional manner, we constructed one mutated form of ENO1, ENO1-mut, which would eliminate the possibility for the alternative form MBP-1 to be translated (Fig. 1). We used the ENO1 cDNA vector as a template for in vitro mRNA to make ENO1 mRNA and a shorter form only including the MBP-1-part of the gene to make MBP-1-mRNA. The ENO1-mut construct was used as a template for in vitro ENO1-mut-mRNA.
We could show that ENO1 mRNA has a strong, dose dependent, inhibitory effect on cell growth in neuroblastoma cells (SK-N-AS). By adding equal amounts of ENO1-mRNA and control-mRNA (EGFP) to the cells, the number of viable cells in the cell culture was decreased by 80% two days after transfection in the ENO1-mRNA-experiment. If 4/5 of the ENO1-mRNA was exchanged with control-mRNA the decrease was 60% two days after transfection (Table 3, Fig. 4). This indicates that ENO1 acts in a dose dependent manner, suggesting that cellular levels of ENO1 might play a crucial role in regulating apoptosis and proliferation in neuroblastoma cells.
Surprisingly the mutated ENO1-mut-mRNA showed very similar effects as the wild type ENO1-mRNA. This might be explained by the fact that ENO1 in fact can bind to the same sites as MBP-1 and act as a transcription factor, even though not as efficiently . Maybe by adding very large amounts of mRNA, this difference is overruled. However, an alternative explanation is that the enolase itself has tumour suppressor activity. This is supported by the observation that 0.3 μg ENO1 mRNA induces a stronger inhibition in cell growth rate (60%) than the same amount of MBP-1-mRNA (40%) in neuroblastoma cells.
A strong effect could also be seen in 293-cells by adding ENO1-mRNA. 80–90% reduction was observed in the 1.5 μg mRNA experiment, while a lower reduction (60%) was observed when 0.3 μg mRNA was used, as was the case with SK-N-AS cells.
A difference between the different mRNAs could also be seen in the 1.5 μg experiment where MBP-1 and ENO1-mut showed a weaker effect than ENO1. Also in the ENO1-mut and MBP-1 experiments, a smaller effect was observed with a lower amount of mRNA (0.3 μg). We conclude that over-expression of ENO1 has the same effect in both neuroblastoma cells and transformed kidney cells, and that ENO1 can function as a general tumour suppressor.
However, the transfection of ENO1-mRNA into K562 cells, a human erythroleukemia cell line, shows only minor differences with control mRNA (Table 3, Fig. 4). This indicates that ENO1-mRNA has no general toxicity to cells but seems to work through one or more specific pathways. ENO1-mRNA does not seem to activate any cell death or growth suppression pathway in the lymphoblast cell line K562, as it seems to do in the neuroblastoma cell line SK-N-AS and the transformed kidney cell line 293. But these are indeed very different types of cells, and are likely to be defective in different cellular pathways.
In order to see whether ENO1 was equally expressed in both low stage and advanced neuroblastomas, and also to compare this with the mRNA-levels in neuroblastoma cell lines, we conducted a real-time-PCR-study using Taqman. Surprisingly no difference in the ENO1-mRNA levels could be detected between 1p-deleted tumours and 1p-intact tumours, neither in the cell lines nor in primary Stage 4 neuroblastoma tumours (Fig. 5). The loss of one allele seems either to be compensated in these cells, or the levels of ENO1-mRNA in the aggressive Stage 4 tumours are suppressed by a different mechanism in the 1p-intact Stage 4 tumours. Even though small sample number (11 primary tumours), we could detect a difference (p = 0.01) in the levels of ENO1-mRNA in Stage 4 neuroblastomas compared to Stage 2 neuroblastomas (Fig. 5). This still needs further studies to be confirmed but one could speculate that the ENO1-mRNA level might be of importance in the aggressiveness of neuroblastoma tumours, as seen in non-small cell lung cancer . The cell lines showed a higher relative concentration of ENO1 than any of the primary tumours (Fig. 5). This might be explained by the different surroundings and state of cells in culture compared to primary tumour cells (Fig. 5). The fact that by adding extra ENO1-mRNA to the cell lines, even though they expressed ENO1 already, made them apoptotic, adds to the hypothesis that the levels of this mRNA might be crucial.
We also did a mutation screening of the exonic sequences of ENO1, including exon/intron boundaries, and of the intronic sequences between exons 4–8, in order to cover the region around the alternative translation start of MBP-1, in genomic DNA of 44 primary neuroblastoma tumours of all different stages. However, no mutations could be found in these regions, indicating that changes in the level of ENO1 expression may result from other types of mutations or from changes in regulatory mechanisms.
In conclusion, our studies demonstrate that ENO1, a gene mapping to a region commonly deleted in advanced neuroblastoma tumours, can act as a strong tumour suppressor by slowing down the cell growth and inducing apoptosis. Although we could not identify any mutations in the coding sequence and immediate promoter region of the gene in 48 primary tumour samples, our studies suggest that variations in the level of expression of the gene can play a role in regulating apoptosis and cell proliferation in neuroblastoma. To prove the hypothesis of the level of ENO1 expression being crucial, future investigations could involve silencing of ENO1 in neuroblastoma cells in vitro, by gene knock down experiments and/or siRNA targeted to the ENO1-mRNA, to detect whether this, opposite adding extra ENO1-mRNA, increases the growth rate. Deletion of the 1p chromosomal region is obviously one way to achieve a reduction in expression of ENO1, but it is not clear whether a reduction in the expression of the second allele is also necessary through other mechanisms in neuroblastoma.
Maris JM, Matthay KK: Molecular biology of neuroblastoma. J Clin Oncol. 1999, 17: 2264-2279.
Martinsson T, Sjoberg RM, Hedborg F, Kogner P: Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 1995, 55: 5681-5686.
Ejeskar K, Sjoberg RM, Abel F, Kogner P, Ambros PF, Martinsson T: Fine mapping of a tumour suppressor candidate gene region in 1p36.2-3, commonly deleted in neuroblastomas and germ cell tumours. Med Pediatr Oncol. 2001, 36: 61-66. 10.1002/1096-911X(20010101)36:1<61::AID-MPO1016>3.0.CO;2-0.
White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, Winter C, Gregory SG, Hogarty MD, Maris JM, Brodeur GM: Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene. 2005, 24: 2684-2694. 10.1038/sj.onc.1208306.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D: Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997, 90: 809-819. 10.1016/S0092-8674(00)80540-1.
Ejeskar K, Sjoberg RM, Kogner P, Martinsson T: Variable expression and absence of mutations in p73 in primary neuroblastoma tumors argues against a role in neuroblastoma development. Int J Mol Med. 1999, 3: 585-589.
Ejeskar K, Abel F, Sjoberg R, Backstrom J, Kogner P, Martinsson T: Fine mapping of the human preprocortistatin gene (CORT) to neuroblastoma consensus deletion region 1p36.3-->p36.2, but absence of mutations in primary tumors. Cytogenet Cell Genet. 2000, 89: 62-66. 10.1159/000015566.
Abel F, Sjoberg RM, Ejeskar K, Krona C, Martinsson T: Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. Br J Cancer. 2002, 86: 596-604. 10.1038/sj.bjc.6600111.
Abel F, Sjoberg RM, Krona C, Nilsson S, Martinsson T: Mutations in the N-terminal domain of DFF45 in a primary germ cell tumor and in neuroblastoma tumors. Int J Oncol. 2004, 25: 1297-1302.
Krona C, Ejeskar K, Abel F, Kogner P, Bjelke J, Bjork E, Sjoberg RM, Martinsson T: Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene. 2003, 22: 2343-2351. 10.1038/sj.onc.1206324.
Krona C, Ejeskar K, Caren H, Abel F, Sjoberg RM, Martinsson T: A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours. Br J Cancer. 2004, 91: 1119-1130.
Yang HW, Chen YZ, Takita J, Soeda E, Piao HY, Hayashi Y: Genomic structure and mutational analysis of the human KIF1B gene which is homozygously deleted in neuroblastoma at chromosome 1p36.2. Oncogene. 2001, 20: 5075-5083. 10.1038/sj.onc.1204456.
Chen YY, Takita J, Chen YZ, Yang HW, Hanada R, Yamamoto K, Hayashi Y: Genomic structure and mutational analysis of the human KIF1Balpha gene located at 1p36.2 in neuroblastoma. Int J Oncol. 2003, 23: 737-744.
Astuti D, Morris M, Krona C, Abel F, Gentle D, Martinsson T, Kogner P, Neumann HP, Voutilainen R, Eng C, Rustin P, Latif F, Maher ER: Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. Br J Cancer. 2004, 91: 1835-1841. 10.1038/sj.bjc.6602202.
Lahti JM, Valentine M, Xiang J, Jones B, Amann J, Grenet J, Richmond G, Look AT, Kidd VJ: Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet. 1994, 7: 370-375. 10.1038/ng0794-370.
Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F, Kogner P: Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer. 1997, 33: 1997-2001. 10.1016/S0959-8049(97)00278-5.
Maris JM, Jensen SJ, Sulman EP, Beltinger CP, Gates K, Allen C, Biegel JA, Brodeur GM, White PS: Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3. Genomics. 1996, 35: 289-298. 10.1006/geno.1996.0359.
Enomoto H, Ozaki T, Takahashi E, Nomura N, Tabata S, Takahashi H, Ohnuma N, Tanabe M, Iwai J, Yoshida H: Identification of human DAN gene, mapping to the putative neuroblastoma tumor suppressor locus. Oncogene. 1994, 9: 2785-2791.
Deed RW, Hirose T, Mitchell EL, Santibanez-Koref MF, Norton JD: Structural organisation and chromosomal mapping of the human Id-3 gene. Gene. 1994, 151: 309-314. 10.1016/0378-1119(94)90676-9.
Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM: Physical mapping and genomic structure of the human TNFR2 gene. Genomics. 1996, 35: 94-100. 10.1006/geno.1996.0327.
Bader SA, Fasching C, Brodeur GM, Stanbridge EJ: Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ. 1991, 2: 245-255.
Subramanian A, Miller DM: Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem. 2000, 275: 5958-5965. 10.1074/jbc.275.8.5958.
Ray R, Miller DM: Cloning and characterization of a human c-myc promoter-binding protein. Mol Cell Biol. 1991, 11: 2154-2161.
Wang W, Wang L, Endoh A, Hummelke G, Hawks CL, Hornsby PJ: Identification of alpha-enolase as a nuclear DNA-binding protein in the zona fasciculata but not the zona reticularis of the human adrenal cortex. J Endocrinol. 2005, 184: 85-94. 10.1677/joe.1.05909.
Feo S, Arcuri D, Piddini E, Passantino R, Giallongo A: ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett. 2000, 473: 47-52. 10.1016/S0014-5793(00)01494-0.
Chaudhary D, Miller DM: The c-myc promoter binding protein (MBP-1) and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. Biochemistry. 1995, 34: 3438-3445. 10.1021/bi00010a036.
Marcu KB, Bossone SA, Patel AJ: myc function and regulation. Annu Rev Biochem. 1992, 61: 809-860. 10.1146/annurev.bi.61.070192.004113.
Ray RB, Steele R, Seftor E, Hendrix M: Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res. 1995, 55: 3747-3751.
Ghosh AK, Steele R, Ray RB: Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice. Cancer Res. 2005, 65: 718-721. 10.1158/0008-5472.CAN-05-0581.
Chang YS, Wu W, Walsh G, Hong WK, Mao L: Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res. 2003, 9: 3641-3644.
Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, De Bernardi B, Evans AE, Favrot M, Freeman AI: International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988, 6: 1874-1881.
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993, 11: 1466-1477.
Caren H, Ejeskar K, Fransson S, Hesson L, Latif F, Sjoberg RM, Krona C, Martinsson T: A cluster of genes located in 1p36 are down-regulated in neuroblastomas with poor prognosis, but not due to CpG island methylation. Mol Cancer. 2005, 4: 10-10.1186/1476-4598-4-10.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/5/161/prepub
We would like to especially acknowledge Dr. Panos Ioannou that spent a lot of energy on this work, but sadly passed away before the completion of the study.
We would like to acknowledge Swegene Genomics Gothenburg for giving us access to their equipment. We gratefully acknowledge the financial support of the Swedish Cancer Society, the Children's Cancer foundation, the King Gustav V Jubilee Clinic Cancer Research Foundation, the Assar Gabrielsson Foundation and Svenska Läkaresällskapet. The work was also partially supported by a grant from the Brockhoff Foundation to PI.
The author(s) declare that they have no competing interests.
KE carried out the functional studies, the expression studies, the exon sequencing, study design and drafted the manuscript. CK and HC carried out the promoter- and intron sequencing. FZ participated in the in vitro mRNA-design and carried out FACS-analysis. LL participated in tissue culture and FACS analysis. TM participated in the design of the mutation analysis study. PI participated in the design and coordination of the functional study and helped to draft the manuscript.
All authors read and approved the final manuscript.
About this article
Cite this article
Ejeskär, K., Krona, C., Carén, H. et al. Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer 5, 161 (2005). https://doi.org/10.1186/1471-2407-5-161